Back to results
US 7,220,553 B2Granted
Use of Russell's viper venom-induced plasma factor Xa activity to monitor the activity of factor Xa inhibitors
AssigneeSanofi-Aventis Deutschland GmbH
InventorValeria Fung-Hwei Chu
Life of this patent
Estimating the term…
Abstract
The invention relates to a method of monitoring the effect of a direct of indirect Factor Xa inhibitors comprising the steps of collecting a plasma sample from a patient, adding a solution of Russell's viper venom to the plasma sample and measuring the clotting time or the residual FXa activity chromogenically.
Claims8
A method of monitoring the effect of Factor Xa (FXa) inhibitors treatment comprising the steps of:
- a) collecting a plasma sample from a mammal that has received an FXa inhibitor;
- b) dividing said plasma sample into portions, saving one portion as the control plasma and adding serial dilutions of FXa inhibitor to other portions;
- c) adding a solution of Russell's viper venom (RVV-X) to plasma samples defined in b);
- d) comparing FXa activity measured for the control plasma with the residual FXa activity measured for the plasma samples with added FXa inhibitor;
- e) constructing a standard curve of dose-dependent inhibition of RVV-X induced by FXa inhibitor;
- and
- f) estimating the concentration of FXa inhibitor at various points in time during the FXa inhibitor treatment by using the standard curve.
4 more elements
A method of monitoring the effect of (FXa) inhibitors treatment comprising the steps of:
- a) collecting a plasma sample from a mammal that has received an FXa inhibitor;
- b) dividing said plasma sample into portions, saving one portion as the control plasma and adding serial dilutions of FXa inhibitor to other portions;
- c) adding a solution of Russell's viper Venom to plasma samples defined in b);
- d) comparing the clotting time measured for the control plasma with that of the plasma samples with added FXa inhibitor;
- and
- e) constructing a dose-dependent clotting time prolongation curve and determining the concentration of a FXa inhibitor required to prolong the clotting time twice longer than the control plasma clotting time.
3 more elements
Dependencies are inferred from the claim text.